Form 4 for SABS SAB Biotherapeutics, Inc.
Accepted 2022-06-07 00:00:00 ET · period of report 2022-06-06 · accession 0001209191-22-034919 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-07 | 2022-06-06 | SABS | Kropotova Alexandra | Chief Medical Off | A - Grant | $0.00 | +300.0K | 300.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-06 | A | A | 300,000 | $0.00 | 300,000 | D | — | — | (F1) Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on June 6, 2023, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date. (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. |